|New from NCI|
|HER2’s Genetic Link to Breast Cancer Spurs Development of New Treatments|
| ||The discovery of the HER2 gene and its role in breast cancer was a turning point in the treatment of the disease. Read how this NCI-supported discovery led to the development of targeted treatments that have helped women with HER2-positive breast cancer live longer.|
|Take with Food: Study Tests Lowering Dose of Prostate Cancer Drug|
| ||Can taking a cancer drug with eating breakfast help lower the dose that patients need to take? Read about a study in which researchers tackled this question.|
|Video—Rectal Cancer: Treatment, Research, and Quality of Life|
If you missed the live broadcast, you can now watch the recording of our Facebook Live event. Listen to Dr. Carmen Allegra, of NCI and the University of Florida, and Dr. Debra Schrag, of Harvard University, discuss rectal cancer treatment, research, and quality of life issues.
|Video—Paying for Clinical Trials|
| ||The latest in our series of videos about clinical trials, this video explains the different types of costs related to taking part in a clinical trial and who is expected to pay for which costs.|
|Access to Experimental Cancer Drugs|
An experimental drug is one that has been tested in the lab and with animals. These drugs are approved for testing in people by the U.S. Food and Drug Administration (FDA) but can’t be advertised, sold, or prescribed yet. Learn about the ways that people with cancer can access experimental drugs.
|Infographic—Investments in Basic Research for Pediatric Cancers|
Learn how investments in basic research can lead to new approaches for cancer prevention, screening, and new treatments, such as dinutuximab (Unituxin) to treat neuroblastoma.
|PDQ Summary Updates|
|Breast Cancer Treatment during Pregnancy|
We’ve updated our PDQ summary about the treatment of breast cancer during pregnancy, including revisions to the tests used to diagnose and stage the disease.
|Oral Cavity, Pharyngeal, and Laryngeal Cancer Screening|
Our PDQ summary on screening for oral cavity and oropharyngeal cancer now includes information on laryngeal and pharyngeal cancer, and the title was changed to reflect the update.
|Drug Information Updates|
|Blinatumomab Use in Leukemia|
We’ve updated our drug information summary to include FDA’s expanded approval for blinatumomab (Blincyto) to treat patients with acute lymphoblastic leukemia whose disease is in complete remission but who are at high risk of their cancer recurring.
|Rucaparib for Ovarian Cancer|
We’ve updated our drug information summary on rucaparib (Rubraca) to include a recent approval by FDA. The drug is now approved to be used as maintenance therapy in patients with ovarian, fallopian tube, or primary peritoneal cancer that is in remission.
No hay comentarios:
Publicar un comentario